On Tuesday, Pro-Dex got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they kick off a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Pro-Dex is currently extended beyond a proper buy zone after clearing the 22.99 buy point in a cup without handle. Be aware that it is a thinly traded stock, with average daily dollar volume under $8 million.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
One weak spot is the company's 73 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company posted 0% earnings growth. Revenue growth fell to 25%, down from 41% in the previous quarter.
Pro-Dex earns the No. 2 rank among its peers in the Medical-Products industry group. Globus Medical is the top-ranked stock within the group.
